# IDP-012

Source: https://onco.cc/drugs/idp-012/  
OnCo record `idp-012` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IDP-012 is an experimental bispecific antibody-drug conjugate from InduPro Therapeutics, in preclinical development for cancer.

## Summary

IDP-012 is a bispecific antibody-drug conjugate (topoisomerase 1 inhibitor payload) from InduPro Therapeutics. A bispecific antibody-drug conjugate against EGFR and the company's undisclosed partner antigen TAPA-E1, carrying a topoisomerase 1 inhibitor payload. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline chart bar ends in the IND-enabling column (HTML data-width 56 across 4 columns); no registered trial found. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: IDP-012
- Modality: Bispecific antibody-drug conjugate (topoisomerase 1 inhibitor payload)
- Mechanism: A bispecific antibody-drug conjugate against EGFR and the company's undisclosed partner antigen TAPA-E1, carrying a topoisomerase 1 inhibitor payload.

## Sources

- InduPro Therapeutics: induprotx.com: https://www.induprotx.com/pipeline

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [InduPro Therapeutics](https://onco.cc/companies/indupro-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/idp-012.json